Dr Nandu graduated from King’s College London in 1988 and has dedicated over 35 years to advancing the field of paediatric endocrinology. He began with a research fellowship in Manchester from 1993 to 1996, publishing extensively on childhood growth and development. After completing clinical training in endocrinology, he was appointed Consultant at Norfolk & Norwich University Hospital in 2002. Over the next 15 years, he established and expanded the paediatric endocrinology service, developed a thriving clinical research unit, and led multiple national and multinational studies.
He served as Chief Investigator for two landmark global trials with Novo Nordisk, which supported the worldwide approval of Levemir (2010) and Tresiba (2015), both of which transformed diabetes care for children.
In 2017, Dr Nandu relocated to Dubai to establish the paediatric endocrine service at Al Jalila Children’s Hospital, the UAE’s first dedicated children’s hospital. Under his leadership, the service has become one of the most respected in the region. He introduced clinical innovations including AI-assisted bone age analysis, novel dynamic testing protocols, advanced genetic diagnostics, and cutting-edge therapies for diabetes, rare bone diseases, lipid disorders, and obesity. He also launched the hospital’s paediatric endocrinology fellowship in 2023, graduating the first cohort of regional specialists the same year.
